Communiqués BioCryst Pharmaceuticals, Inc.

Actions

BCRX

US09058V1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 03/09/2026			Varia. 5j.	Varia. 1 janv.
10,09 ^USD	-0,79 %		+2,23 %	+29,36 %

25/08	BioCryst Pharmaceuticals annonce l’autorisation de mise sur le marché d’ORLADEYO pour les patients pédiatriques atteints d’AOH au Japon	CI
25/08	BioCryst Pharmaceuticals obtient l'approbation au Japon pour l'Orladeyo chez les jeunes enfants	MT

Communiqués

01/09	BioCryst to Present at Upcoming Investor Conference	AQ
25/08	BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan	AQ
05/08	BioCryst: Q2 Earnings Snapshot	AQ
05/08	BioCryst Reports Second Quarter 2026 Financial Results	AQ
22/07	BioCryst to Report Second Quarter 2026 Financial Results on August 5	AQ
15/07	BioCryst Appoints David W. Jenkins as Chief Scientific Officer	GL
02/07	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
29/06	BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility	GL
12/06	BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting	AQ
09/06	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
27/05	BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting	AQ
13/05	BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026	AQ
06/05	BioCryst: Q1 Earnings Snapshot	AQ
06/05	BioCryst Pharmaceuticals : Q1 2026 Earnings Presentation	PU
06/05	BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/05	BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema	AQ
28/04	BioCryst to Present at Upcoming Investor Conferences	AQ
15/04	BioCryst to Report First Quarter 2026 Financial Results on May 6	AQ
06/04	BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
06/04	BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer	AQ
03/04	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/03	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/02	BioCryst: Q4 Earnings Snapshot	AQ
26/02	BioCryst Pharmaceuticals : BCRX Q4 2025 Earnings Presentation	PU